Cytogen, Inc. Overview
Cytogen is a small-cap Korean precision-medicine company that began as a pure-play developer of circulating tumour cell (CTC) liquid biopsy technology. Its core asset is a proprietary high-density microporous (HDM) chip and the Smart Biopsy™ platform. The platform isolates CTCs from blood by size, without labels, and keeps the cells alive, so they can be cultured, single-cell sequenced and turned into organoids. Commercial traction from CTC services alone was minimal for a decade: revenue was below KRW 1.2 B in every year through 2022. Since a December 2023 change of control to the CanDx Holdings consortium, Cytogen has diversified through acquisitions. It bought a US CLIA/CAP toxicology lab (ExperTox) in January 2023 and Korea's self-described number-one NIPT/PGT provider (Genomecare) in August 2024. It has also added medical-device distribution. Revenue reached KRW 26.1 B in FY2025, but the company remains loss-making. Management now presents Cytogen as a "life-cycle precision medicine" platform spanning fertility genomics, cancer diagnostics and an early-stage anti-metastasis drug programme.
The company's own description
In its periodic reports, Cytogen describes itself as a CTC-based liquid biopsy platform company. It uses proprietary "Live CTC" isolation technology to provide biomarker analysis and companion-diagnostic assay development for pharmaceutical companies developing oncology drugs (Q1 2026 quarterly report, as summarized by ValueLine). The same filing summary lists the main activities:
-
CTC analysis services for pharmaceutical companies on the Smart Biopsy™ platform
-
Data provision and kit supply for research institutions
-
Precision-medicine diagnostic services
-
Global expansion through the acquisition of a Texas CLIA lab and the establishment of a Japanese subsidiary
-
Diversification into medical-device distribution and health-functional-food sales
-
Acquisition of the prenatal/postnatal diagnostics company Genomecare in 2024, to secure stable cash flow
The Q1 2026 quarterly report states that the August 2024 Genomecare acquisition, which covers PGT and NIPT across the journey from IVF to delivery, "improved cash flow and strengthened consolidated financial results" (KIND, Q1 2026 quarterly report extract).
In July 2026, explaining the Genomecare merger, the company said it now has two core businesses:
-
CTC-based precision medicine, framed as the future growth engine
-
Prenatal and pre-implantation genetic testing, which already generates stable profits
The stated ambition is to become a "full life-cycle precision medicine company", from pre-implantation genetic testing through prenatal diagnosis to cancer precision diagnosis and treatment support (Seoul Economic Daily / SEN TV, 29 July 2026).
Business model and revenue model
| Revenue stream | Model type | Description | Approximate share |
|---|---|---|---|
| Genome technology development and analysis services (Genomecare: NIPT, PGT) | Fee-for-service diagnostics, mostly B2B2C via fertility and obstetric clinics | Per-test fees for non-invasive prenatal testing and pre-implantation genetic testing | ~47% of revenue (Q2 2026 basis) |
| Liquid biopsy application business | Mixed: services (B2B pharma contract analysis; Japanese premium out-of-pocket tests), product sales (Smart Biopsy™ instruments, chips, kits), equipment contracts (e.g. digital lab-on-chip automation system), plus distribution of medical devices and health-functional food | CTC enumeration and characterization, drug-efficacy evaluation, CDx assay development; Japan CTC services; distribution | ~48% (Q2 2026 basis) |
| Toxicology and molecular diagnostics (ExperTox, Houston, Texas) | Fee-for-service laboratory testing | CLIA/CAP-accredited toxicology testing for 100+ US hospitals and labs | ~6% (Q2 2026 basis) |
| Licensing / royalties | Not a material disclosed stream | Out-licensing of anti-metastasis candidates is contemplated, not yet realized | 0% |
Cytogen's revenue model has four layers:
The segment mix is from the Butler.works summary of DART filings ("Liquid Biopsy application 48% · Genome technology development and analysis service 47% · Toxicology and molecular diagnostics 6%", 2026 Q2 revenue basis). The shares sum to 101% because of rounding at source.
Two points stand out. First, a large portion of the "Liquid Biopsy application" segment appears to consist of low-margin distribution revenue rather than CTC technology revenue. Medical-device distribution (for example, medical gloves) generated KRW 1.5 B in Q3 2024 alone (thebell, March 2025). Second, the precise split between CTC services, equipment and distribution inside that segment is not publicly disclosed in accessible summaries.
Value-chain position
CTC business: Cytogen sits upstream as a platform developer and instrument maker (HDM chip, isolator, stainer, imaging analyser). It sits midstream as a GCLP-certified central lab offering analysis services. In Japan it is beginning to move downstream into patient-facing (B2C) out-of-pocket testing through hospital partners such as Japan's National Cancer Center Hospital.
Genomecare: A downstream clinical laboratory service provider. It receives samples from fertility clinics and obstetricians and returns NGS/AI-based genetic reports.
ExperTox: A downstream US reference laboratory.
Customer types and end-markets
| Customer type | Examples (disclosed) | End-market |
|---|---|---|
| Global and domestic pharma/biotech | Daiichi Sankyo (2018 AXL biomarker research); pharma clients in Japan via CMIC marketing agreement | Oncology drug development (biomarkers, CDx) |
| Hospitals / academic medical centres | Samsung Medical Center, Asan Medical Center, Seoul National University Hospital, Seoul St. Mary's, Severance, Gangnam Severance; Japan NCCH | Clinical research, precision oncology |
| Government / research institutes | US NIH (platform supply, 2022); Gangwon Regional Public Procurement Service (2025 automation-system contract) | Research infrastructure |
| Fertility clinics and obstetricians (Genomecare) | Described as "top fertility hospitals nationwide" (names not disclosed) | Reproductive genomics (NIPT, PGT) |
| US hospitals and labs (ExperTox) | 100+ hospitals and labs in Houston, Texas | Toxicology testing |
Independent characterization
On the evidence, Cytogen is not a scaled CTC diagnostics company. It is a holding-like small cap whose consolidated revenue is now driven by an acquired reproductive-genomics lab and by distribution activities. That revenue funds a sub-scale but technically differentiated CTC platform and a newly announced drug-discovery venture.
The NIPT/PGT unit is genuinely profitable: FY2025 standalone operating margin was about 27%. It is the economic anchor. The CTC franchise has struggled for more than a decade to convert scientific credibility into recurring revenue. That credibility includes NIH platform supply, Japanese NCCH collaboration and AACR presentations.
The strategy pursued since 2024 under CanDx-aligned management (portfolio diversification, bio-robotics, PRP automation, anti-metastasis drugs) widens the scope considerably relative to the company's balance sheet. The repeated governance conflicts between the founder and the controlling shareholder are a distinctive feature of the investment case.
Strategy
Stated strategy (themes from company disclosures)
Cytogen's corporate statement (Korean Wikipedia, drawing on company material):
Mission: "pursue optimal solutions for a better future for humanity".
Vision: "global leader in liquid biopsy leading human health".
-
Five management strategies, including:
-
advancement of the CTC business strategy
-
acceleration of new-business development
-
increase in future value
-
Under CEO Ahn (from February 2026) the themes are:
-
Simplify decision-making to maximize execution.
-
Advance CTC technology and achieve "real results in global markets".
-
Build new growth axes: BioRobot division, precision and regenerative medicine, and infertility solutions via Genomecare. The goal is to evolve from a CTC single-business structure into a "global precision-medicine platform company".
-
Sustainable profitability: "establish a sustainable revenue model and increase corporate value".
-
Balance R&D and stable earnings. Ahn stated that a bio company needs both future-facing R&D capability and a stable profit base, and that the Genomecare acquisition and merger were consistent steps toward that goal (July 2026).
Strategic initiatives in the last 24 months (Oct 2024–Oct 2026)
| Initiative | Date | Description | Targets / status |
|---|---|---|---|
| Founder–controller settlement and co-CEO structure | Jan–Mar 2025 | Ended the Hyulim Networks-backed dispute; founder ran CTC, Ahn ran new businesses | Superseded by sole-CEO structure (Feb 2026) |
| 2025 "top-line growth" plan | Mar 2025 | Aggressive promotion in the US and Japan; domestic drug-monitoring analysis services with clinical-stage biotechs; Genomecare expected to deliver KRW 10 B+ annual revenue; medical-device distribution | Genomecare delivered KRW 10.96 B (FY2025) |
| Digital lab-on-chip automation system | Nov 2025 | First government equipment contract (KRW 1.05 B) | Delivery by Nov 2026 |
| BioRobot division | Feb 2026 | Combines cell-based diagnostics with automation | Newly created; no revenue disclosed |
| Head-office move to Gwacheon | Mar 2026 | Relocation to Gwacheon Urban Hub, a growing pharma/bio cluster | Completed |
| Anti-metastasis drug programme | Jul 2026 | CTC-derived omics data used to discover and validate targets | Non-clinical completion in 3–4 years; early-stage out-licensing contemplated |
| Genomecare absorption merger | Jul–Oct 2026 | Integrates fertility genomics into parent; removes duplicate costs; cash flow redeployed to CTC advancement, anti-metastasis drugs and next-generation reproductive medicine | Completed 1 Oct 2026 |
| Reproductive-medicine synergies | From Jul 2026 | Embryo-biopsy cell QC standardization; cell-based NIPT; PRP automation linked to fertility clinics | R&D / early commercialization |
| Japan three-pillar push | 2,026 | CTC, PRP and prenatal testing in Japan; BioJapan participation (third year) | Ongoing |
| Two national R&D projects | Sep 2026 | Extend the CTC "diagnosis → treatment" value chain | Selected |
| Employee incentive alignment | Aug 2026 | 400,000 stock options to 11 staff at KRW 3,280 (exercisable 2028–2033). Total outstanding options 1,016,791 shares. | Granted |
ESG / cost programmes / medium-term targets
Cost programme: "company-wide efficient SG&A reduction" cited for the Q1 2026 improvement. No quantified target disclosed.
Medium-term financial targets / guidance: not publicly disclosed. A 2023 aspiration of about 50% average annual revenue growth (founder Jeon, Feb 2023) was a stated expectation, not formal guidance.
ESG commitments: none disclosed.
Products & Services
CTC / Liquid Biopsy Platform (Smart Biopsy™)
| Product / service | Description and key capabilities | Target customer | Launch / latest version | Pricing |
|---|---|---|---|---|
| HD Microporous (HDM) Chip | Semiconductor-process microfluidic filter chip. Captures CTCs by size, label-free (no EpCAM dependence), driven by gravity to minimize cell damage. Enables "Live CTC" isolation for downstream culture and molecular work. | Labs, pharma, hospitals | Core technology since about 2008–2012 | — |
| Smart Biopsy™ Cell Isolator (CIS030 referenced) | Automated enrichment of CTCs from 5–10 ml of blood or body fluid. Company-reported recovery rate of 79–82%. | Clinical labs, research institutes, pharma | Model CIS030 referenced in KoreaRatings 2024 tech report | — |
| Smart Biopsy™ IF Stainer (CST030 referenced) | Automated immunofluorescent staining (anti-EpCAM, anti-CD45, anti-CK and other markers) | Same | Referenced 2024 | — |
| Smart Biopsy™ Cell Image Analyzer | Multi-channel fluorescent imaging and analysis. Company states it cut analysis time from about 3 hours to 30 minutes. | Same | — | — |
| Time-lapse Incubator | Monitors cell growth and images cells in culture plates (for CTC culture) | Research | — | — |
| CTC enumeration and characterization services (GCLP lab) | Isolation, counting and phenotyping; protein biomarkers such as PD-L1 | Pharma (clinical trials), hospitals | Commercial since 2012 | Per sample (not disclosed). In 2017–18 the company said PD-L1 liquid biopsy could cost 1/5–1/10 of tissue biopsy. |
| Drug-efficacy evaluation / biomarker discovery and validation | Uses CTCs and CTC culture/animal models to test anticancer drug response | Pharma / biotech | Ongoing | Contract-based |
| Companion-diagnostic (CDx) assay development | Develops CTC-based assays to select patients for targeted therapies | Pharma | Ongoing | Contract-based |
| CTC single-cell RNA sequencing | Single-cell transcriptomics of isolated CTCs (e.g. Gangnam Severance breast cancer study, 2023; Macrogen collaboration) | Hospitals, research | 2022–2023 | Contract-based |
| CTC 3D organoids / drug sensitivity testing | Organoid culture from patient CTCs to select personalized therapy | Hospitals, patients | In development / research use | — |
| Japan CTC analysis services (CytoGen Japan) | Local CTC testing; targets the non-reimbursed premium out-of-pocket market | Japanese hospitals, patients, pharma | Revenue began late 2025 | — |
| Digital lab-on-chip automated production system (chip automation system) | Automated line for producing digital lab-on-chip devices; KRW 1.05 B contract with Gangwon Regional Public Procurement Service (Chuncheon) | Public-sector / regional bio-cluster | Contract Nov 2025, delivery by Nov 2026 | KRW 1.05 B per system (VAT excl.) |
| Pet cancer diagnostics; AI data analysis | Listed among offerings by a data vendor | Veterinary / data clients | — | — |
Sources for the platform: Yahoo Finance and Simply Wall St company descriptions; Biospectator; Dealsite (Jul 2023); KoreaRatings tech report (Aug 2024); Digital Today (Nov 2025); Craft.co.
Reproductive Genomics ("Genomecare by CytoGen")
| Product / service | Description | Target customer | Notes |
|---|---|---|---|
| NIPT (non-invasive prenatal testing) | cfDNA-based fetal chromosomal aneuploidy screening from maternal blood; AI/NGS-based | Obstetric clinics, pregnant women | Company claims domestic No.1 position in NIPT and PGT (company statement) |
| PGT (pre-implantation genetic testing): Genobro™ (지노브로) | Analyses cells biopsied from IVF embryos to select chromosomally normal embryos, aiming to raise implantation and pregnancy rates and lower miscarriage risk | Fertility (IVF) clinics | Supplied to "top fertility hospitals nationwide" |
| Cell-based NIPT (R&D) | Isolation and analysis of rare fetal-origin cells (e.g. circulating trophoblasts) in maternal blood, using Cytogen's rare-cell platform; meant to complement cfDNA NIPT | Future | Medium/long-term R&D (announced Jul 2026) |
| Embryo biopsy QC / standardized pre-processing | Uses Cytogen's rare-cell imaging and handling to standardize PGT trophectoderm-cell QC | Fertility clinics | Planned post-merger synergy |
Toxicology & Molecular Diagnostics (ExperTox, USA)
| Service | Description | Customers |
|---|---|---|
| Toxicology testing | CLIA-certified, CAP-accredited lab founded 1996; specializes in toxicology tests | 100+ hospitals and research labs in Houston; the company cited Abbott and other pharma/hospitals as main partners (2023) |
| Molecular diagnostics (expansion) | Was pursuing additional CAP accreditation in molecular diagnostics at acquisition; intended as the US platform for CTC services | US clinical market |
At acquisition, ExperTox revenue was about US$3 M (2022), with net margin above 20% excluding COVID testing (company statement, Jan 2023).
New / Diversified Businesses
| Business | Description | Status |
|---|---|---|
| Medical-device distribution | Distribution of items such as medical gloves | KRW 1.5 B revenue in Q3 2024 (thebell). Ongoing. |
| Health-functional food sales | Sale of health-functional foods | Ongoing (size not disclosed) |
| PRP (platelet-rich plasma) automatic separation/extraction system | Automated PRP processing to be linked with Genomecare's fertility-clinic network (infertility solutions); also targeted at Japan | Under development. Regulatory and clinical evidence being built "step by step". |
| BioRobot division | Combines cell-based diagnostics with automation for lab/test automation | Division created Feb 2026 |
| Anti-metastasis drug development | Uses CTC isolation and omics data to find and validate anti-metastatic targets | Discovery stage. Non-clinical completion guided at 3–4 years. Early out-licensing considered. |
| Precision / regenerative medicine | Integrated diagnosis-to-treatment value chain | Strategic intent; details not disclosed |
Financial Narrative
Basis and sources. Consolidated K-IFRS, fiscal years ending 31 December.
-
Revenue, operating income and net income FY2021–FY2025: Butler.works and ETFshopping summaries of DART.
-
FY2025 exact figures: DART preliminary results disclosure (Digital Today, 13 Feb 2026).
-
FY2024 and FY2025 balance-sheet totals: DART-based KorMedi and Digital Today reports.
-
FY2024 cash and gross profit: Craft.co.
-
FY2025 cost of sales: ValueLine (DART-sourced).
-
EPS: ETFshopping (DART).
Blank cells mean the item is not publicly disclosed in sources reviewed.
Margins (chartable)
Margins are derived from rounded figures. FY2021–FY2022 margins are distorted by negligible revenue.
Revenue CAGR FY2021–FY2025. About 205% per year (from KRW 0.3 B to KRW 26.05 B). This is mathematically correct but analytically misleading: almost all of the growth is acquired (ExperTox from 2023, Genomecare from August 2024) or comes from distribution. Organic CTC revenue growth is not separately disclosed.
Quarterly trajectory (chartable)
Notes:
-
Q3 2025: Thinkpool (DART).
-
Q1 and Q2 2026: ETFshopping and Seoul Economic Daily. Q1 2026 revenue +14.0% YoY, operating loss narrowed from KRW 2.4 B. Q2 2026 revenue +8.7% YoY.
-
Q2 2025 operating income, Q1/Q2 2025 net income and all Q4 2025 figures are back-calculated from reported YoY changes and full-year totals. They are approximate and not company-reported quarterly figures.
Trailing twelve months to Q2 2026 (derived). Revenue about KRW 27.35 B; operating loss about KRW 6.6 B; net loss about KRW 10.5 B. The net loss is consistent with Investing.com's TTM EPS of KRW −457 × 23.1 M shares ≈ KRW −10.6 B.
Balance sheet (chartable)
Notes:
-
The parent's separate total assets were KRW 54.64 B at FY2025 (JobKorea).
-
Current ratios are from THE VC's AI summary: 539.2% (2023), 1,318.8% (2024), 286.6% (most recent). The FY2024 spike likely reflects cash from the December 2023 KRW 55.5 B raise. Morningstar reports a TTM current ratio of 2.93x and a quick ratio of 2.59x (April 2026).
-
Implied equity at H1 2026 is about KRW 33 B. This is derived from Butler's P/B of 2.10x at KRW 3,025 and is not a reported figure.
-
Net debt, working capital and debt maturities are not publicly disclosed in sources reviewed. for disclosed convertible bonds.
Cash flow
Cash-flow statement line items were not accessible in sources reviewed. No cash dividends or buybacks have been paid in the company's listed history; it has used treasury shares only for employee compensation (60,000 shares disposed in Sep–Nov 2025).
Commentary: trends, inflections, drivers
Revenue inflection is acquisition-led. Revenue of KRW 0.3–1.2 B a year from 2018 to 2022 shows that the CTC franchise did not achieve commercial scale in its first eight years after listing. The step-ups in FY2023 (+318.6%) and FY2024 (+242.6%) coincide with the consolidation of ExperTox (January 2023) and Genomecare (from 21 August 2024). FY2025 (+138.8%) is the first full year of Genomecare. The company's own explanation of FY2025 growth is "expansion of new businesses and growth of consolidated subsidiary Genomecare". Q1 2026 growth (+14%) was attributed to Genomecare and new Japanese revenue that began in late 2025.
Growth is decelerating sharply now that acquisitions have annualized. YoY growth slowed from +129% in Q3 2025 to +14% in Q1 2026 and +8.7% in Q2 2026. The next inflection depends on organic drivers (Japan CTC, PRP, NIPT/PGT volume), not M&A.
Losses are narrowing but persistent.
-
Operating losses have stayed in a narrow band of KRW 10.7–12.9 B for four years, then improved to KRW 8.16 B in FY2025. H1 2026 operating loss was KRW 2.7 B versus about KRW 4.3 B in H1 2025.
-
Improvement comes mostly from Genomecare's profit contribution and SG&A cuts. Management cited "company-wide efficient SG&A reduction".
-
The parent's separate operating loss (KRW −7.77 B in FY2025) shows the CTC business is still structurally unprofitable.
Net losses exceed operating losses. Net loss exceeded operating loss by about KRW 4.2 B in FY2025 and KRW 6.4 B in FY2024. Non-operating losses therefore account for a substantial share. Plausible contributors include valuation losses on convertible instruments, impairments and financial costs. The specific breakdown is not publicly disclosed in sources reviewed.
Gross margins are low for a diagnostics company. About 21.5% in FY2025 (cost of sales KRW 20.44 B). This reflects the mix: lab-service cost structures plus pass-through distribution revenue. The cost-of-sales breakdown (ValueLine, TTM) shows raw materials of about KRW 18.8 B. That is consistent with significant merchandise and consumables content.
Balance-sheet erosion. Total equity fell from KRW 48.9 B to KRW 36.0 B in FY2025, roughly equal to the net loss. Implied equity is about KRW 33 B at H1 2026. The KRW 5.2 B 7th-series CB issued in May 2026 for operating funds signals that the company keeps returning to capital markets. Cash runway cannot be calculated precisely without the cash-flow statement, but the cadence of financing suggests a runway measured in a few years at most at current burn, absent further improvement.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Segment (As Reported, Translated) Overview
| Segment (as reported, translated) | Korean label (approximate) | Contents | Main entities |
|---|---|---|---|
Liquid Biopsy Application Business | Liquid Biopsy 응용사업 | CTC services (pharma contract analysis, Japan CTC services), Smart Biopsy™ instruments/chips/kits, equipment contracts, medical-device distribution, health-functional food sales | Cytogen, Inc. (parent); CytoGen Japan |
Genome Technology Development & Analysis Services | 게놈기술개발 및 분석서비스 | NIPT, PGT (Genobro™), other reproductive genomic testing | Genomecare (subsidiary until 30 Sep 2026; merged into parent on 1 Oct 2026) |
Toxicology & Molecular Diagnostics | 독성 및 분자진단 | US CLIA/CAP toxicology testing; molecular diagnostics expansion | ExperTox Inc. (Houston, Texas) |
Segment Revenue
| Segment | Share of revenue, 2026 Q2 basis (%) | Implied H1 2026 revenue (KRW Bn, derived) |
|---|---|---|
Liquid Biopsy Application | 48 | 6.3 |
Genome Technology & Analysis | 47 | 6.2 |
Toxicology & Molecular Diagnostics | 6 | 0.8 |
Total | 101 (rounding at source) | 13.2 |
Segment revenue (KRW Bn)
| Segment revenue (KRW Bn) | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Genome Technology & Analysis: Genomecare standalone revenue (full year) | — | — | 10.96 |
Parent company separate revenue (Cytogen, Inc.) | 0.87 | 5.26 | 12.49 |
Consolidated revenue (all segments) | 3.2 | 10.9 | 26.1 |
Segment Metric Details
| Segment metric (KRW Bn) | FY2025 |
|---|---|
Genomecare standalone operating income | 2.95 |
Genomecare standalone net income | 2.69 |
Genomecare standalone operating margin (%) | 26.9 |
Parent separate operating income | -7.77 |
Consolidated operating income | -8.16 |
Group Entities
| Entity | Country | Ownership | Status / function |
|---|---|---|---|
Cytogen, Inc. | Korea | Listed parent | CTC platform, R&D, distribution; since 1 Oct 2026 also runs NIPT/PGT (former Genomecare) |
ExperTox Inc. | USA (Houston, TX) | 100% (acquired Jan 2023) | CLIA/CAP toxicology lab; US base for CTC services |
CytoGen Japan | Japan (Tokyo) | 100% (119,999 shares; book value KRW 1.093 B per Q1 2026 report) | CTC analysis services, Japanese market development |
CytoGen Health Inc. | USA | — | US subsidiary established 2022 |
Genomecare Co., Ltd. | Korea | Was 99.89%, later 100%; dissolved by absorption merger on 1 Oct 2026 | Merged into parent |
Income Statement and Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue (KRW Bn) | 0.3 | 0.8 | 3.2 | 10.91 | 26.05 |
Revenue growth YoY (%) | -15.9 | 118.7 | 318.6 | 242.6 | 138.8 |
Gross profit (KRW Bn) | — | — | — | 1.7 | 5.6 |
Operating income (KRW Bn) | -12.9 | -11.5 | -11.8 | -10.7 | -8.16 |
Net income (KRW Bn) | -10.9 | -18.8 | -15.8 | -17.1 | -12.33 |
EPS basic (KRW) | -642 | -1,063 | -862 | -758 | -535 |
Dividends per share (KRW) | 0 | 0 | 0 | 0 | 0 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansMargin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Gross margin (%) | — | — | — | 15.6 | 21.5 |
Operating margin (%) | -4,300 | -1,438 | -369 | -98.1 | -31.3 |
Net margin (%) | -3,633 | -2,350 | -494 | -156.9 | -47.3 |
Income Statement
| Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|---|
Revenue (KRW Bn) | 5.6 | 6.3 | 7.63 | 6.5 | 6.4 | 6.8 |
Operating income (KRW Bn) | -2.4 | -1.9 | -1.31 | -2.6 | -1.5 | -1.2 |
Net income (KRW Bn) | -2.5 | -2.8 | -1.62 | -5.4 | -1.3 | -2.2 |
Balance Sheet and Financial Ratios (x)
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Total assets (KRW Bn) | — | 72.5 | 62.2 |
Cash and equivalents (KRW Bn) | — | 31.2 | — |
Total liabilities (KRW Bn) | — | 23.5 | 26.2 |
Total equity (KRW Bn) | — | 48.9 | 36.0 |
Current ratio (x) | 5.39 | 13.19 | 2.87 |
Financial Analysis
| Metric (KRW Bn) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Dividends paid | 0 | 0 | 0 | 0 | 0 |
Share buybacks | 0 | 0 | 0 | 0 | 0 |
Instrument by Date
| Date | Instrument | Amount (KRW Bn) | Counterparty | Terms |
|---|---|---|---|---|
Nov 2018 | IPO | 15.6–20.4 (band) | Public | Band KRW 13,000–17,000 |
Sep 2020 | 3rd CB | 10.0 | Jeil Bio Fund (7.0), T&C Asset Mgmt (3.0) | 0% coupon; conversion price KRW 20,200; maturity 25 Sep 2025 |
28 Dec 2023 | Third-party rights issue | 40.0 | CanDx Holdings | 3,125,000 shares (KRW 12,800/share implied) |
28 Dec 2023 | CB | 15.5 | CanDx Holdings | Originally KRW 30 B, cut to KRW 15.5 B and payment brought forward. |
Aug 2024 | Third-party rights issue | 6.5 | Theragen Etex | 706,445 shares (3.05%) |
May 2026 | 7th CB (private, bearer, unsecured) | 5.2 | — | 0% coupon; conversion price KRW 5,445; conversion from 26 May 2027 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2025 value | Basis |
|---|---|---|
ROE (%) | -29.0 | Net income / average equity ((48.9 + 36.0)/2) |
ROE (%), vendor | -19.96 (normalized, Morningstar); -33.22 (ValueLine) | Vendor methodologies differ |
ROA (%) | -18.3 | Net income / average assets ((72.5 + 62.2)/2) |
ROA (%), vendor | -10.52 (normalized, Morningstar) | — |
ROIC (%), vendor | -10.03 (normalized, Morningstar) | — |
Current ratio (x) | 2.87–2.93 | THE VC; Morningstar |
Total liabilities / equity (x) | 0.73 | 26.2 / 36.0 |
Equity ratio (%) | 57.9 | 36.0 / 62.2 |
Net debt / EBITDA | Not meaningful (negative EBITDA; net debt not disclosed) | — |
Interest coverage (x) | -4.96 | Morningstar, TTM April 2026 |
Asset turnover (x) | 0.39 | 26.05 / average assets 67.35 |
Region revenue (KRW Bn)
| Region revenue (KRW Bn) | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Domestic (Korea) | — | — | 23.38 |
Export / overseas | — | — | 2.66 |
Total | 3.2 | 10.91 | 26.05 |
TTM revenue split (KRW Bn)
| TTM revenue split (KRW Bn) | TTM Mar 2025 | TTM Jun 2025 | TTM Sep 2025 | TTM Dec 2025 |
|---|---|---|---|---|
Domestic | 11.57 | 18.59 | 23.07 | 23.38 |
Export | 4.13 | 2.21 | 2.02 | 2.66 |
Segment Overview
| Segment | Primary geography |
|---|---|
Genome Technology & Analysis (Genomecare) | Korea, about 100% |
Toxicology & Molecular Diagnostics (ExperTox) | United States, about 100% |
Liquid Biopsy Application | Korea (CTC services, distribution, equipment) plus Japan (CytoGen Japan services from late 2025) |
Share Price History
| Date | Price (KRW) | Context | Source |
|---|---|---|---|
Nov 2018 | 13,000–17,000 (IPO band) | KOSDAQ listing | Medical Times |
16 Dec 2019 | 11,900 | Market cap KRW 67 B; 5.634 M shares | Kiwoom Securities |
27 Oct 2021 | 66,100 | Pre-dates an apparent roughly 3x increase in share count by 2023; not comparable without adjustment | Asia Economy |
Early Jan 2024 | 16,200 | Start of 2024 | Pharm Edaily |
27 Nov 2024 | 4,850 | During management dispute | Pharm Edaily |
5 Nov 2025 | 2,975 | — | Digital Today |
19 Dec 2025 | 6,250 (intraday limit-up 6,700) | Theme rally | JoongAng Economy News |
22 Dec 2025 | 8,120 (limit-up) | Animal-alternative testing bill | Seoul Economic Daily |
30 Dec 2025 | 8,990 | Market cap about KRW 207.9 B | BioTimes |
Dec 2025 / Jan 2026 | 11,200 | — | TipRanks, Investing.com |
24 Feb 2026 | 4,930 | After CEO change | Money Today |
13 Apr 2026 | 3,955 | Market cap KRW 91.7 B | Morningstar |
29 Jul 2026 | 2,830 | Merger announcement day (−6.45%) | KorMedi |
10 Aug 2026 | 3,670 | EGM day (+7%) | KorMedi |
1 Oct 2026 | 3,225 | Merger completion (+6.09%) | Money Today |
12 Oct 2026 | 2,770 | Market cap KRW 64.06 B | Investing.com |
14 Oct 2026 | 2,865 | Market cap about KRW 66.5 B | StockHub |
Approximate Change by Period
| Period | Approximate change | Basis |
|---|---|---|
1-year | About −4% | KRW 2,975 (5 Nov 2025) to KRW 2,865 (14 Oct 2026); window not exactly 12 months |
Since 2024 start | About −82% | KRW 16,200 to KRW 2,865 |
From December 2025 peak | About −74% | KRW 11,200 to KRW 2,865 |
3-year | Strongly negative | Judal.co.kr's April 2026 "3-year price index 26.59%" metric is not interpretable without methodology |
5-year | Not computed | — |
Valuation Multiples
| Multiple | Cytogen | Basis |
|---|---|---|
P/E | Not meaningful (loss-making) | TTM EPS KRW −457 (Investing.com) |
P/B (x) | About 1.8–2.1 | KRW 66.3 B market cap / FY2025 equity KRW 36.0 B = 1.84x; Butler shows 2.10x at KRW 3,025 |
P/S, TTM (x) | About 2.4 | KRW 66.3 B / TTM revenue about KRW 27.35 B (derived) |
EV/Sales; EV/EBITDA | Not computed | TipRanks EV field appears corrupted ("₩65.07K"). |
Peer comparison | Not compiled | — |
Capital Instruments
| Instrument | Issue date | Principal (KRW Bn) | Coupon / YTM (%) | Conversion price (KRW) | Maturity | Status |
|---|---|---|---|---|---|---|
3rd CB | Sep 2020 | 10.0 | 0 / 0 | 20,200 | 25 Sep 2025 | — |
CB to CanDx | 28 Dec 2023 | 15.5 | — | — | — | — |
7th CB (private) | May 2026 | 5.2 | 0 / 0 | 5,445 | — | Outstanding; conversion from 26 May 2027 |
Analyst Conclusions
Management guidance
No formal quantitative guidance is published. Qualitatively, management signals:
-
a "turnaround" foundation from M&A synergies and visible overseas revenue (Q1 2026 release)
-
cost synergies and simpler decision-making from the Genomecare merger
-
Japan expansion across three product lines
-
a 3–4 year horizon to complete non-clinical work on anti-metastasis candidates
Consensus expectations
None (no sell-side coverage).
Bull case
-
Hidden profitable core. Genomecare earned KRW 2.95 B of operating profit in FY2025 at about a 27% margin. If CTC losses are cut through merger synergies and SG&A discipline, consolidated breakeven is within reach. TTM operating loss has already narrowed to about KRW 6.6 B, against KRW 10.7 B in FY2024.
-
Asset value versus market cap. At about KRW 66 B market cap (about 1.8–2.1x book), investors pay roughly the price of a profitable domestic NIPT/PGT lab plus the US lab and Japan subsidiary. That leaves the CTC platform (52 patents, NIH/NCCH validation) and the anti-metastasis option close to free.
-
Japan as a real growth vector. Revenue began in late 2025. A premium out-of-pocket market with higher CTC awareness, NCCH collaboration and CMIC channel access could make Japan the first market where CTC testing scales commercially for Cytogen.
Bear case
-
Growth has stalled after the acquisitions annualized. Revenue growth decelerated to +8.7% YoY in Q2 2026. The underlying CTC business generated minimal revenue for a decade. Low gross margins (about 21.5%) and distribution revenue cap profit potential.
-
Governance and overhang. The founder was removed as CEO by dismissal, the controlling PE-backed vehicle is selling shares (−758,794 shares, Sep 2026), and the board is controller-dominated. Further contests or a disorderly exit by CanDx are plausible.
-
Funding and dilution treadmill. Equity fell 26% in FY2025 and the company issued another CB in May 2026. With 1.02 M options outstanding and an expanding R&D agenda (drug discovery, bio-robotics, PRP), further dilutive raises are likely before sustainable profitability.
Key catalysts and monitorables (next 12 months)
| Timing | Catalyst / monitorable |
|---|---|
| About 12 Nov 2026 | Q3 2026 results: first post-merger quarter commentary; YoY growth rate; operating loss trend |
| Nov 2026 | Delivery and acceptance of the KRW 1.05 B Gangwon automation system (contract end 5 Nov 2026) |
| Q4 2026 – Q1 2027 | Segment-reporting presentation after the merger; FY2026 results (around Feb–Mar 2027) |
| Ongoing | CanDx Holdings large-holding reports (further stake reductions or a block sale) |
| Ongoing | Board dynamics with founder Jeon; any renewed shareholder activism |
| 2026–2027 | Japanese revenue disclosure; PRP system regulatory progress; cell-based NIPT development |
| Feb 2027 | CEO Ahn's director term expiry (20 Feb 2027); re-appointment at the March 2027 AGM |
| From 26 May 2027 | 7th CB conversion window opens (KRW 5,445 conversion price, well above current price) |
| Ongoing | National R&D project milestones; anti-metastasis target nominations |
| Ongoing | Korean animal-alternative testing legislation (theme catalyst) |
Analyst verdict
Cytogen today is two businesses tied together by a controlling shareholder's diversification strategy.
The first is a credible, profitable Korean reproductive-genomics laboratory. Genomecare, now merged into the parent, produced KRW 10.96 B of revenue and a 27% operating margin in FY2025. It is the reason consolidated revenue grew roughly 87-fold between FY2021 and FY2025 and the reason losses are narrowing.
The second is the original CTC liquid biopsy franchise. It is scientifically differentiated by live, label-free cell capture and validated through collaborations with NIH, Japan's NCCH and leading Korean hospitals. Commercially, however, it remains marginal more than seven years after its 2018 IPO, and it now carries a broadening, capital-hungry agenda: Japanese services, PRP automation, bio-robotics and anti-metastasis drug discovery.
The market has priced this tension harshly. The shares trade near KRW 2,800, about 74% below the speculative December 2025 peak. That implies a market capitalization of about KRW 66 B, or roughly 2x book and 2.4x trailing sales. On a sum-of-the-parts view this valuation is undemanding if Genomecare's earnings are durable and CTC cash burn is contained.
However, three factors justify a significant discount and argue against treating Cytogen as a conventional diagnostics value play:
Governance: a controller-dominated board, the founder's dismissal and the controller's stake sales.
Funding: recurring convertible-bond issuance and 26% equity erosion in FY2025.
Growth: decelerating top-line growth now that acquisitions have annualized.
The investment case rests on evidence that has not yet appeared:
-
consolidated operating breakeven after the merger
-
disclosed and growing Japanese CTC revenue
-
no further dilutive financing
-
an orderly resolution of CanDx's ownership intentions
Until then, Cytogen is best characterized as a high-risk, event-driven small cap whose fundamental floor is set by its NIPT/PGT franchise. Upside optionality lies in Japan and CTC-derived therapeutics, and the principal risks are governance and dilution.
APPENDIX A: DATA GAPS AND DISCREPANCIES
| Item | Issue |
|---|---|
| Founding year | DART-based sources: 18 Mar 2010. Some aggregators: 2013 (likely error). Job portal: 16 Mar 2010. |
| Head office | Registry shows Gwacheon (since Mar 2026); some data vendors still list Seoul (Songpa) |
| Employees | 39 (annual report, domestic parent) vs 43–47 (pension data) vs 50–56 (vendors) |
| EPS | FY2025 EPS KRW −535 (DART via ETFshopping) vs KRW −236.49 (Investing.com "earnings release" row; basis unclear) |
| Genomecare acquisition price | KRW 13.18 B (Cytogen filing, 99.88%) vs KRW 6.8 B (third-party database, Theragen's portion) |
| CanDx current stake | 31.96% (FY2025 report) vs about 28.7% implied after the Sep 2026 reduction vs 30.79% shown by an aggregator against a Sep 2026 date (possibly stale) |
| CTC market size | US$5.5 B to US$14 B (2024–2025) depending on research house |
| Q2 2025 and Q4 2025 quarterly figures | Back-calculated, not directly reported in sources reviewed |
| R&D expense, cash flow, debt detail, auditor, ISIN | Not accessible in sources reviewed; available in Korean DART filings |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Title | Tenure | Prior roles | Education | Age / birth | Compensation |
|---|---|---|---|---|---|---|
Ahn Ji-hoon (안지훈) | CEO (sole Representative Director); inside director | Joined 1 Feb 2024 (strategy, new business, M&A); co-CEO 2 Jan 2025; sole CEO 20 Feb 2026; director term to 20 Feb 2027 | Strategic Planning Head, Samkwang Medical Foundation; CEO, Samkwang LabTree (Mar 2019–Jan 2021); CEO, SML Genetree (Mar 2016–Feb 2023) | PhD coursework (ABD), Science & Technology Management, Korea University | Born Oct 1981 (44) | Not disclosed (below the KRW 500 M individual disclosure threshold or not reported); granted 80,000 stock options at KRW 3,280 (Aug 2026) |
Jeon Byung-hee (전병희) | Founder; inside director (non-executive role since Feb 2026) | CEO from founding until July 2024; co-CEO Jan 2025–Feb 2026 (removed by board) | Founder | — | Born 1959 (Yahoo Finance) | — |
Son Young-woong (손영웅) | Executive Director (전무); inside director | — | — | — | — | 80,000 stock options (Aug 2026); holds 0.14% |
Jung Yun-young (정윤영) | Executive Director (전무) | — | — | — | — | 80,000 stock options (Aug 2026) |
Lee Jong-gil (이종길) | Senior Managing Director | — | — | — | — | Holds 2.03% (FY2025) |
Jang Kang-won (장강원) | Director (이사, officer) | — | — | — | — | 20,000 stock options |
Park Se-hyung (박세형) | Principal Researcher, Diagnostics Division | — | — | — | — | — |
“—” = not publicly disclosed.
Board of Directors — Ahn Ji-hoon
| Name | Category | Appointed | Background | Affiliation |
|---|---|---|---|---|
Ahn Ji-hoon | Inside director, CEO | 2024 | See above | CanDx-aligned (per thebell) |
Jeon Byung-hee | Inside director | Founder | Founder | Founder |
Son Young-woong | Inside director, Executive Director | — | — | Founder-aligned (per thebell) |
Min Seung-ki (민승기) | Non-executive director | Re-elected 10 Aug 2026 (3-year term) | CEO, Excelsior Capital Korea; formerly VP Keystone PE, VP HTC Financials, EVP Hyundai Securities, EVP Heungkuk Asset Management, EVP Heungkuk Life; born Sep 1962 | CanDx / Excelsior |
Seo Seok-chan (서석찬) | Non-executive director | Elected 10 Aug 2026 (3-year term) | CEO, Wells Bio; formerly strategy director, B-Light Investment (an Access Bio subsidiary and CanDx co-investor); VP AI business, MHN City; branch manager, OSTEM USA San Francisco; born Aug 1975 | CanDx-aligned (inferred via B-Light) |
Noh Kyung-hwa (노경화) | Non-executive director | Mar 2025 | — | CanDx-aligned (per thebell count; not individually confirmed) |
Chae Gwang-seok (채광석) | Outside director | Oct 2023 EGM | Former CEO, DS Asset Management; Songhyun Investment; Hanwha Asset Management | Not specified |
Bang Nam-ho (방남호) | Outside director | Sep 2024 | — | Not specified |
Jang In-geun (장인근) | Outside director | 12 Mar 2025 EGM (company nominee) | — | Not specified |
“—” = not publicly disclosed.
Board & Management Changes
| Date | Change | Context |
|---|---|---|
28 Feb 2024 | Sa Cheol-gi appointed co-CEO alongside founder Jeon | Post-CanDx change of control |
5 Jul 2024 | Jeon resigns as co-CEO; Sa becomes sole CEO | Followed board votes in which founder-aligned directors (Jeon, Kim Jung-won, Nam Kwang-min) were outvoted on reorganization and M&A items |
2 Jan 2025 | Sa resigns; Jeon and Ahn appointed co-CEOs | Settlement of the 2024 management dispute. Jeon took responsibility for the CTC business; Ahn for new businesses. |
20 Feb 2026 | Jeon removed as co-CEO by board resolution; Ahn sole CEO | Thebell flagged that dismissal rather than resignation leaves "embers of conflict". The company said Jeon agreed and the aim was management efficiency. |
Major Shareholders
| Rank | Holder | Category | Stake (%) |
|---|---|---|---|
| 1 | CanDx Holdings LLC | Investment vehicle (Excelsior Capital Korea-led) | 31.96 |
| 2 | Jeon Byung-hee | Inside director, founder | 8.84 |
| 3 | Kiwoom High-Growth Gazelle Fund | SME/venture investment fund | 4.49 |
| 4 | Kim Jin-wook | Major individual shareholder | 3.62 |
| 5 | Lee Jong-gil | Senior Managing Director | 2.03 |
| 6 | T&C Asset Management | Private fund manager | 1.73 |
| 7 | Son Young-woong | Executive | 0.14 |
| — | Minority shareholders (19,612 holders) | Retail | 40.72 |
| — | National Pension Service | Listed as a holder (THE VC, updated Jul 2026) | Stake not disclosed |
| — | Foreign investors | — | About 2% (Dec 2025) |
Competitive Landscape
Competitors by Segment
| Segment | Competitor | HQ | Positioning vs Cytogen |
|---|---|---|---|
CTC platforms | Menarini Silicon Biosystems (CellSearch®; DEPArray™) | Italy / US | CellSearch is the first FDA-cleared CTC system (prognosis in metastatic breast, prostate and colorectal cancer); dominant installed base; EpCAM-based. Far larger, with regulatory moat. |
CTC platforms | ANGLE plc (Parsortix®) | UK | Size-based, label-free CTC capture (closest technological analogue); FDA-cleared for metastatic breast cancer (2022) |
CTC / single-cell liquid biopsy | Epic Sciences | US | CTC-based diagnostic tests; pharma services |
CTC / microfluidics | Fluxion Biosciences; Cynvenio Biosystems | US | Microfluidic CTC isolation for research |
CTC (Japan) | Sysmex Corporation | Japan | Developed a microfluidic CTC capture device (2023); strong Japanese IVD incumbent in Cytogen's target market |
ctDNA liquid biopsy (substitute) | Guardant Health; GRAIL; Natera | US | ctDNA tests dominate clinical liquid biopsy (CGP, MCED, MRD). Cytogen positions CTC as complementary rather than competing. |
Korean liquid biopsy / genomics | Macrogen; Labgenomics; EDGC | Korea | Labgenomics and EDGC also pursue US liquid biopsy expansion; Macrogen is both partner and competitor |
NIPT / PGT (Korea) | GC Genome; Theragen Bio / Theragen Etex group; Labgenomics; EDGC | Korea | Domestic NIPT/PGT competitors. Theragen Etex was the former owner of Genomecare. |
US toxicology labs | Large reference labs (Quest Diagnostics, Labcorp) and regional toxicology labs | US | ExperTox is a small regional player |
CTC/organoid theme peers (Korean market) | Other KOSDAQ organoid / animal-alternative testing companies | Korea | Compete for the same investor theme |
Peer Comparison FY2025
| Metric | Cytogen (FY2025) | Menarini Silicon Biosystems |
|---|---|---|
Revenue | KRW 26.05 B (about US$19 M at about 1,400 KRW/US$; indicative) | Not separately disclosed (private division of Menarini Group) |
Revenue growth (%) | 138.8 | — |
Operating margin (%) | -31.3 | — |
FDA-cleared CTC product | No | Yes (CellSearch) |
“—” = not publicly disclosed.



